195 related articles for article (PubMed ID: 26900365)
1. Corrigendum to "Uroncor consensus statement: Management of biochemical recurrence after radical radiotherapy for prostate cancer: From biochemical failure to castration resistance". [Rep. Pract. Oncol. Radiother. 20 (2015) 259-272].
López Torrecilla J; Hervás A; Zapatero A; Gómez Caamaño A; Macías V; Herruzo I; Maldonado X; Gómez Iturriaga A; Casas F; González San Segundo C
Rep Pract Oncol Radiother; 2016; 21(1):90-2. PubMed ID: 26900365
[TBL] [Abstract][Full Text] [Related]
2. Corrigendum to "Why should radiation oncology do translational research?" [Rep Pract Oncol Radiother 2019;24(1):60-64].
Cañas R; Linares I; Guedea F; Berenguer Francés MÁ
Rep Pract Oncol Radiother; 2019; 24(2):151. PubMed ID: 30723386
[TBL] [Abstract][Full Text] [Related]
3. Erratum to "Identification of patient's requirements in quality management system implemented in health care institutions" [Rep Pract Oncol Radiother 17 (2012) 50-53].
Kaźmierczak D; Bogusz-Czerniewicz M
Rep Pract Oncol Radiother; 2012; 17(3):176-185. PubMed ID: 24377021
[TBL] [Abstract][Full Text] [Related]
4. Erratum to: "Pancreatic cancer and SBRT: A new potential option?" [Rep. Pract. Oncol. Radiother. 20 (2015) 377-384].
Hajj C; Goodman KA
Rep Pract Oncol Radiother; 2015; 20(6):491. PubMed ID: 26696790
[TBL] [Abstract][Full Text] [Related]
5. Uroncor consensus statement: Management of biochemical recurrence after radical radiotherapy for prostate cancer: From biochemical failure to castration resistance.
López Torrecilla J; Hervás A; Zapatero A; Gómez Caamaño A; Macías V; Herruzo I; Maldonado X; Gómez Iturriaga A; Casas F; González San Segundo C
Rep Pract Oncol Radiother; 2015; 20(4):259-72. PubMed ID: 26109913
[TBL] [Abstract][Full Text] [Related]
6. Erratum to "Technical note: Accuracy checks of physical beam modifier factors algorithm used in computerized treatment planning system for a 15 MV photon beam" [Rep. Pract. Oncol. Radiother. 14 (2009) 214-220].
Muhammad W; Maqbool M; Shahid M; Ahmad M; Matiullah M
Rep Pract Oncol Radiother; 2010; 15(1):25. PubMed ID: 24376919
[TBL] [Abstract][Full Text] [Related]
7. Reply to Carl J. Rossi's Comment on "Proton beam and prostate cancer: An evolving debate" by Anthony Zietman [Rep. Pract. Oncol. Radiother. 2013;18:338-42].
Zietman A
Rep Pract Oncol Radiother; 2013; 18(6):344. PubMed ID: 24416577
[No Abstract] [Full Text] [Related]
8. Verification of the Elekta Monaco TPS Monte Carlo in modelling radiation transmission through metals in a water equivalent phantom.
Byrnes K; Ford A; Bennie N
Australas Phys Eng Sci Med; 2019 Jun; 42(2):639-645. PubMed ID: 30863988
[TBL] [Abstract][Full Text] [Related]
9. Comment on "Proton beam and prostate cancer: An evolving debate" by Anthony Zietman [Rep. Pract. Oncol. Radiother. 2013;18:338-42].
Rossi CJ
Rep Pract Oncol Radiother; 2013; 18(6):343. PubMed ID: 24416576
[No Abstract] [Full Text] [Related]
10. Consensus on management of castration-resistant prostate cancer on behalf of the Urological Tumours Working Group (URONCOR) of the Spanish Society of Radiation Oncology.
Gómez-Caamaño A; González-San Segundo C; Henríquez I; Maldonado X; Zapatero A;
Clin Transl Oncol; 2019 Apr; 21(4):420-432. PubMed ID: 30293231
[TBL] [Abstract][Full Text] [Related]
11. Optimising Radiation Therapy Dose to the Swallowing Organs at Risk: An In Silico Study of feasibility for Patients with Oropharyngeal Tumours.
Barnhart MK; Cartmill B; Ward EC; Brown E; Sim J; Saade G; Rayner S; Robinson RA; Simms VA; Smee RI
Dysphagia; 2019 Dec; 34(6):869-878. PubMed ID: 30741335
[TBL] [Abstract][Full Text] [Related]
12. Corrigendum to "Adjuvant and first line chemotherapy use for endometrial cancer" [Gynecol. Oncol. Rep. 41 (2022) 101002].
Knisely A; Huang Y; Li Y; Prabhu VS; Wright JD
Gynecol Oncol Rep; 2023 Apr; 46():101112. PubMed ID: 37082519
[TBL] [Abstract][Full Text] [Related]
13. Corrigendum to "Co-existent abdominoperitoneal tuberculosis with endometrial cancer: A diagnostic and surgical challenge" [Gynecol. Oncol. Rep. 37 (2021) 100848].
Ashraf M; Goh WA; Tan EMX; Nadarajah R
Gynecol Oncol Rep; 2021 Nov; 38():100861. PubMed ID: 34977315
[TBL] [Abstract][Full Text] [Related]
14. Corrigendum to "Metastatic hepatoid carcinoma of ovarian origin - A case report from Northern Pakistan" [Gynecol. Oncol. Rep. 21 (2017) 24-27].
Mahmood H; Fatima H; Faheem M
Gynecol Oncol Rep; 2017 Nov; 22():117. PubMed ID: 29296656
[TBL] [Abstract][Full Text] [Related]
15. Consensus statement on definition, diagnosis, and management of high-risk prostate cancer patients on behalf of the Spanish Groups of Uro-Oncology Societies URONCOR, GUO, and SOGUG.
Henríquez I; Rodríguez-Antolín A; Cassinello J; Gonzalez San Segundo C; Unda M; Gallardo E; López-Torrecilla J; Juarez A; Arranz J
Clin Transl Oncol; 2018 Mar; 20(3):392-401. PubMed ID: 28785912
[TBL] [Abstract][Full Text] [Related]
16. Corrigendum to "Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance" [Gynecol. Oncol. Rep. 34 (2020) 100648].
Oh J; Barve M; Senzer N; Aaron P; Manning L; Wallraven G; Bognar E; Stanbery L; Horvath S; Manley M; Nemunaitis J; Walter A; Rocconi RP
Gynecol Oncol Rep; 2021 May; 36():100740. PubMed ID: 34095420
[TBL] [Abstract][Full Text] [Related]
17. Corrigendum to "Brain metastasis in advanced serous borderline tumor of the ovary: A case presentation" [Gynecol. Oncol. Rep. 22 (2017) 9-12].
Martin M; Grisham RN; Turashvili G; Halpenny DF; Aghajanian CA; Makker V
Gynecol Oncol Rep; 2017 Nov; 22():118. PubMed ID: 29296657
[TBL] [Abstract][Full Text] [Related]
18. Corrigendum to "Interaction between lymphopenia, radiotherapy technique, dosimetry, and survival outcomes in lung cancer patients receiving combined immunotherapy and radiotherapy" [Radiother Oncol 150 (2020) 114-120].
Chen D; Patel RR; Verma V; Ramapriyan R; Barsoumian HB; Angelica Cortez M; Welsh JW
Radiother Oncol; 2021 May; 158():332-334. PubMed ID: 33714536
[No Abstract] [Full Text] [Related]
19. Corrigendum to "Geometric uncertainties in voluntary deep inspiration breath hold radiotherapy for locally advanced lung cancer" [Radiother. Oncol. 118 (2016) 510-514].
Josipovic M; Persson GF; Dueck J; Peter Bangsgaard J; Westman G; Specht L; Aznar MC
Radiother Oncol; 2019 Apr; 133():230. PubMed ID: 30773227
[No Abstract] [Full Text] [Related]
20. Corrigendum to "Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG oncology study (NRG-GY008)" [Gynecol. Oncol. Rep. 31 (2020) 100532].
Santin AD; Filiaci V; Bellone S; O'Cearbhaill R; Ratner ES; Mathews CA; Cantuaria G; Gunderson CC; Rutledge T; Buttin BM; Lankes HA; Birrer MJ
Gynecol Oncol Rep; 2020 Aug; 33():100590. PubMed ID: 32885014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
